| Literature DB >> 35696141 |
Chun-Hsien Chen1, Chun-Chi Wang1,2, Po-Yun Ko3, Yen-Ling Chen4,5,2.
Abstract
The abuse of illicit drugs has been prevalent in recent years and is associated with crime and public health issues. To strengthen public security and fortify public health services with respect to the increasing severity of drug abuse, academic and government institutes have been devoted to constructing relative analytical methods for illicit drugs. To date, the development of sensors has been greatly emphasized due to their features of high sensitivity, prompt detection and flexible manipulation; thus, sensors can serve as alternatives to conventional sophisticated instruments. Recently, the use of nanomaterials has inspired the development of a series of innovative sample pretreatment and detection strategies in the field of analytical chemistry. Herein, this review elaborated the application of nanomaterials in analytical methods, including sample pretreatments, colorimetric sensors and fluorescent sensors. The utilization of nanomaterials in the analytical field provides novel perspectives for the development of detection platforms and facilitates the monitoring of illicit drugs in diverse complex matrices.Entities:
Year: 2020 PMID: 35696141 PMCID: PMC9261814 DOI: 10.38212/2224-6614.1137
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Regulations of cut-off levels of illicit drugs in Taiwan, EU and USA.
| Taiwan (TFDA | EU (EMCDDA | USA (HHS | |||
|---|---|---|---|---|---|
|
|
|
| |||
| Urine (ng/mL) | Whole blood (ng/mL) | Oral fluid (ng/mL) | Urine (ng/mL) | Oral fluid (ng/mL) | |
| Benzodiazepines | 100 | 140 (Diazepam) | 5 (Diazepam) | - | - |
| Amphetamine | 500 | 20 | 360 | 250 | 25 |
| Methamphetamine | 500 | 20 | 410 | 250 | 25 |
| MDMA | 500 | 20 | 270 | 250 | 25 |
| Morphine | 300 | 10 | 95 | 2000 | 15 |
| Codeine | 300 | 10 | 94 | 2000 | 15 |
| Cocaine | - | 10 | 170 | - | 8 |
| Benzoylecgonine | 150 | 50 | 95 | 100 | 8 |
| Ketamine | 100 | - | - | - | - |
| Norketamine | 100 | - | - | - | - |
| THC | 15 | 1.0 | 27 | 15 | 2 |
Abbreviation:
TFDA: Food and Drug Administration (Taiwan),
EMCDDA: European Monitoring Centre for Drugs and Drug Addiction,
HHS: United States Department of Health and Human Services.
Various magnetic nanomaterial-based adsorbents for analysis of illicit drugs.
| Surface functionalized MNPs | Sample volume | Adsorbent amount | Extraction time | Desorption time | Analytical Instrument | Enrichment factor | Sample | Limit of detection | Ref. |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Carbon | 5 mL | 40 mg | 2 min | 5 min | HPLC-UV | - | Urine | 20 ng/mL for methamphetamine | [ |
| Carbon | 6 mL | 15-mm iron wire | 10 min | 5 min | HPLC-UV | - | Urine | 5 ng/mL for amphetamine | [ |
| SMPS@PLS | 1 mL | 10 mg | 21 min | 10 min | HPLC-MS | - | Urine | 0.09 ng/mL for benzoylecgonine | [ |
| MPS | 50 mg | 15 mg | 20 min | 10 min | HPLC-UV | 208.69 | Hair | 0.1 ng/mL for morphine | [ |
|
| |||||||||
|
| |||||||||
| polypyrrole | 30 mg | 2 min | 1 min | HPLC-UV | 310 | Urine | 0.33 ng/mL for methamphetamine | [ | |
| o-MWNTs | 4 mL | 15 mg | 10 min | 10 min | GC-MS | - | Blood | 44 pg/mL for methamphetamine | [ |
| CNTs | 500 μL | 9 mg | 2 min | 2 min | GC-MS | - | Breast milk | 1.5 ng/mL for benzoylecgonine | [ |
| rGO/AgNC | 2 mL | 100 mg | 15 min | - | HPLC-UV | 1000 | Blood | 2.1 pg/mL for codeine | [ |
| Urine | 1.8 pg/mL for morphine | ||||||||
| MNGO | 10 mL | 40 mg | 25 min | 15 min | HPLC-UV | 168 | Urine | 30 ng/mL for methamphetamine | [ |
|
| |||||||||
|
| |||||||||
| 5′-HS(CH2)6-TTTTTGGGAGTCAAGAACGAA-3′ | 25 μL | 0.05 mg | 40 min | - | UV | - | Plasma | 15 ng/mL for cocaine | [ |
|
| |||||||||
|
| |||||||||
| amphetamine antibody methamphetamine antibody | 20 μL | 0.01 mg | 10 min | 10 min | MALDI-TOF | Urine | 1.87 ng/mL for amphetamine | [ | |
Abbreviation:
SMPS@PLS: SiO2 and methacrylic acid-3-(trimethoxysilyl) propyl ester-divinyl benzene and vinyl pyrrolidone core-shell,
MPS: methacrylic acid-3-(trimethoxysilyl) propyl ester,
o-MWNTs: acid-oxidized multi-walled carbon-nanotubes,
rGO/AgNC: reduced graphene oxide/silver nanocomposite,
MNGO: magnetic nano graphene oxide.
Fig. 1Colorimetric strategies for illicit drugs based on nanomaterials which combine with versatile analytical platforms.
Various nanomaterial-based colorimetric sensors for analysis of illicit drugs.
| Nanomaterial-based colorimetric sensors | Sample volume | Incubation time | Sample | Limit of detection | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Citrate-capped AuNPs | 1 mL | - | Bone | 0.62 μg/mL for codeine sulfate | [ |
| Citrate-capped AuNPs | 1.2 mL | 10 min | Urine | 0.3 μg/mL for codeine | [ |
| Citrate-capped AuNPs | - | 10 min | Serum | 0.15 μg/mL for morphine | [ |
| Melamine-modified AuNPs | - | 3 min | Blood | 0.28 ng/mL for clonazepam | [ |
| Melamine-modified AuNPs | - | 10 min | Serum | 2.7 ng/mL for codeine | [ |
| Urine | 4.9 ng/mL for morphine | ||||
|
| |||||
|
| |||||
| (A) Oligonucleotide-assisted aggregation | |||||
| Complementary strand-modified AuNPs and cocaine aptamer | - | 10 s | - | No LOD (for cocaine) | [ |
| Cocaine aptamer fragment 1-modified AuNPs and cocaine aptamer fragment 2-modified AuNPs | 10 μL | 30 min | Fingerprints | 90 ng for cocaine | [ |
| (B) Salt-induced self-assembly | |||||
| AuNPs and cocaine aptamer fragment 1 & 2 | 2 μL | 2–3 min | - | 0.6 μg/mL for cocaine | [ |
| AuNPs and cocaine aptamer | 20 μL | 30 min | Urine | 0.3 ng/mL for cocaine | [ |
| AuNPs and cocaine aptamer | 18.2 μL | 30 min | - | 0.25 mg/mL for cocaine | [ |
| Aptamer sequence: 5′-GGCGACAAGGAAAATCCTTCAACGAAGTGGGTCGCC-3′ | |||||
| AuNPs and cocaine aptamer fragment 1 & 2 | 1 μL | 5 min | - | 2.36 μg for cocaine | [ |
| AuNPs and methamphetamine aptamer | 120 μL | 5 min | Urine | 0.12 μg/mL for methamphetamine | [ |
|
| |||||
|
| |||||
| AgNPs | - | 30 min | Hashish | 52 ng/mL for cannabidiol | [ |
| Complementary strand-modified Au@AgNPs and methamphetamine/cocaine aptamer | 10 μL | - | Urine | 15 pg/mL for methamphetamine | [ |
| Aptamer sequence (methamphetamine): 5′-ACGGTTGCAAGTGGGACTCTGGTAGGCTGGGTAATTTGG-3′ | 0.15 ng/mL for cocaine | ||||
| Complementary strand (methamphetamine)-modified Au@AgNPs and methamphetamine aptamer | 5 μL | 30 min | Waste water | 75 pg/mL for methamphetamine | [ |
| Complementary strand (cocaine)-modified AuNPs and cocaine aptamer | 1 ng/mL for cocaine | ||||
| Cocaine antibody-modified MNPs | 80 μL | 10 min | Urine | 5 ng/mL for cocaine | [ |
| Benzoylecgonine mAb conjugated AuNPs | 100 μL | - | Synthetic saliva | 10 ng/mL for cocaine | [ |
Abbreviation: AuNPs: gold nanoparticles; AgNPs: silver nanoparticles; Au@AgNPs: gold-silver core-shell nanoparticles.
Incubation time: the time of recognition of the analyte in sensing procedure.
Fig. 2Fluorometric strategies for illicit drugs based on nanomaterials which were constructed as fluorophore or quencher and utilized to establish diverse sensing mechanisms.
Various nanomaterial-based fluorescent sensors for analysis of illicit drugs.
| Nanomaterial-based fluorescent sensors | Sample volume | Incubation time | Sample | Limit of detection | Ref |
|---|---|---|---|---|---|
|
| |||||
| (A) Salt-induced self-assembly | |||||
| DNA-CuNCs and cocaine aptamer | 15 min | 30 ng/mL for cocaine | |||
| Aptamer sequence: 5′-GACAAGGAAAATCCTTCAATGAAGTGGGTC-3′ | - | - | [ | ||
| DNA-AgNCs and cocaine aptamer fragment 1 & 2 | - | 15 min | - | 30 ng/mL for cocaine | [ |
| DNA-AgNCs and cocaine aptamer | 5 μL | 1 h | Serum | 0.6 ng/mL for cocaine | [ |
| DNA-AgNCs and cocaine aptamer Aptamer sequence: 5′-GCTGCAGAATGGGATCTTCATGACAAGGAAAATCCTTCAATGAAGTGGGTCAATTAT-3′ | - | 30 min | - | 91 ng/mL for cocaine | [ |
| DNA-AgNCs and ketamine aptamer | 30 μL | 5 min | Blood | 60 pg/mL for ketamine | [ |
| AgNCs | - | 3 min | Urine | No LOD for MDA, MDMA, codeine, meperidine, methcathinone | [ |
| (B) FRET-based fluorescent sensors | |||||
| Cocaine aptamer-modified AuNPs and complementary strand-modified SNPs | 10 μL | 40 min | Serum | 89 pg/mL for cocaine | [ |
| Complementary strand-modified AuNPs and cocaine aptamer | 3 μL | 1 h | - | No LOD for cocaine | [ |
| Cocaine aptamer and AuNPs | 5 μL | 4 h | - | 9.1 ng/mL for cocaine | [ |
| Aptamer sequence (cocaine aptamer fragment 1): 5′-AMCA-AGACAAGGAAAA-3′ | |||||
| AuNPs | - | 3 min | Serum | 19 pg/mL (serum) for morphine | [ |
| Urine | 17 pg/mL (urine) for morphine | ||||
| NTS@SNPs | 29equivalents | 5 min | - | No LOD for methamphetamine | [ |
| Cocaine aptamer fragment 1-modified SNPs and cocaine aptamer fragment 2 | 80 μL | 25 min | Serum | 25 pg/mL for cocaine | [ |
| (C) Control-released fluorescent sensors | |||||
| Pseudorotaxane capped mesoporous SNPs complementary strand-modified NAA and cocaine aptamer | 100 μL | 2 h | Water | 0.94 μg/mL for MDMA | [ |
| 100 μL | 20 min | Saliva | 0.15 μg/mL for cocaine | [ | |
| Aptamer sequence: 5′-TTTTGGGGGGGGGAGACAAGGAAAATCCTTCAATGAAGTGGGTCTCCAGGGGGGTTTT-3′ | |||||
|
| |||||
|
| |||||
| morphine antibody-labeled CdS@MAA-QDs | 0.2 μL | - | - | No LOD for morphine | [ |
| Morphine antibody-labeled CdSe/ZnS QDs | 100 μL | - | Soup | 0.27 ng/mL for morphine | [ |
| 7-aminoclonazepam antibody-modified CdTe-QDs | - | 15 min | Urine | 21 pg/mL for 7-aminoclonazepam | [ |
| Complementary strand-modified QDs and cocaine aptamer | - | - | - | 0.15 μg/mL for cocaine | [ |
| Complementary strand-modified QDs and cocaine aptamer Aptamer sequence: 5′-ACTCATCTGTGAATCTCGGGAGACAAGGATAAATCCTTCAATGAAGTGGGTCTCCC-3′ | 80 μL | 5 min | - | 36 μg/mL for cocaine | [ |
| AuNPs-conjugated cocaine aptamer-modified QDs | 25 μL | 3 h | Artificial urine | 40 pg/mL for cocaine | [ |
| Aptamer sequence: 5′-C6-NH2-AGACAAGGAAAATCCTTCAATGAAGTGGGTCG-SH2-C3-3′ | 480 ng/mL for benzoylecgonine | ||||
| L-cysteine capped CdS QDs | - | - | Urine | 1.8 ng/mL for methamphetamine (fluorescence) | [ |
| D-Cysteine molecules-functionalized CdSe QDs | - | - | - | 17 ng/mL for L-morphine | [ |
| Streptavidin-QDs, complementary strand-modified AuNPs and cocaine aptamer | 10 μL | 25 min | - | 0.15 pg/mL for cocaine | [ |
|
| |||||
|
| |||||
| Methamphetamine aptamer-modified CDs and CoOOH nanosheets | - | 20 min | 0.48 ng/mL for methamphetamine | [ | |
| CDs | 1.5 mL | 5 min | Beverage | 2.0 μg/mL for nitrazepam | [ |
| CDs-functionalized paper | 10 μL | 10 min | Urine | 1.3 μg/mL for 4-chloroethcathinone | [ |
| GQDs | - | 1 min | - | 1.48 μg/mL for methamphetamine | [ |
| GQDs with antimorphine (antibody) | - | - | - | 18 ng/mL for morphine | [ |
| GO and cocaine aptamer fragment 1 & 2 | - | 10 min | Plasma | 30 pg/mL for cocaine | [ |
| GO and cocaine aptamer Aptamer sequence: 5′-GGGAGACAAGGAAAATCCTTCAATGAAGTGGGTCTCCCTAGTTTTCTAGGGAGAC-PO4-3′ | 20 μL | 20 min | Urine | 57 ng/mL for cocaine | [ |
| Cocaine aptamer fragment 1-modified GQDs and cocaine aptamer fragment 2-modified AuNPs | 1 μL | 1 h | Plasma | 30 ng/mL for cocaine | [ |
| Aptamer sequence (fragment 1): 5′-NH2-(CH2)6-TTTTTGGGAGTCAAGAACGAA-3′ | Serum | ||||
| Aptamer sequence (fragment 2): 5′-SH-(CH2)6-TTCGTTCTTCAATGAAGTGGGACGACA-3′ | Saliva | ||||
| Urine | |||||
|
| |||||
|
| |||||
| Cocaine aptamer fragment-modified AuNPs and UCNPs | 2 μL | 40 min | Rat plasma | LOQ: 3 ng/mL (aqueous solution) for cocaine | [ |
| Aptamer sequence: 5′-SH-TTTTTACAGCAGGGTGAAGTAACTTCTTG-3′ | Saliva | LOQ: 15 ng/mL (saliva) for cocaine | |||
| Cocaine aptamer-modified UCNPs | 0.1–10 μg | 30 min | Fingerprints | 0.1 μg for cocaine | [ |
Abbreviation: CuNCs: copper nanoclusters; AgNCs: silver nanoclusters; MDA: 4,5-methylene-dioxy amphetamine; MDMA: 3,4-methylene dioxy methamphetamine; SNPs: silica nanoparticles; NTS: 4-thiophene-N-propyl(trithoxysilane)1,8-naphthalimide; NAA: nanoporous anodic alumina; MAA: mercaptoacetic acid; CDs: carbon dots; CoOOH: cobalt oxyhydroxide; GQDs: graphene quantum dots; GO: graphene oxide; UCNPs: upconversion nanoparticles.
Incubation time: the time of recognition of the analyte in sensing procedure.